NCT05455034 is a Phase 1, PHASE2 clinical trial of single-cell sequencing in Pneumonitis, sponsored by Xinqiao Hospital of Chongqing.

Who is sponsoring NCT05455034?

NCT05455034 is sponsored by Xinqiao Hospital of Chongqing.

What drugs are being tested in NCT05455034?

Interventions in NCT05455034: single-cell sequencing.

What condition does NCT05455034 study?

NCT05455034 studies Pneumonitis.

Is NCT05455034 still recruiting?

NCT05455034 is currently recruiting now. Last updated 14 July 2025.

Last reviewed 2025-07-14 · How we verify

NCT05455034

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis

Recruiting now Phase 1, PHASE2 Last updated 14 July 2025

What this trial tests

Phase 1, PHASE2 trial testing single-cell sequencing in Pneumonitis in 40 participants. Currently enrolling.

Timeline

1 August 2023

Primary endpoint
30 December 2025

30 December 2025

Quick facts

Lead sponsor	Xinqiao Hospital of Chongqing
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 August 2023
Primary completion	30 December 2025
Estimated completion	30 December 2025
Sites	1 location across China

Drugs / interventions tested

single-cell sequencing

Conditions studied

Pneumonitis — all drugs for Pneumonitis →

Sponsor

Xinqiao Hospital of Chongqing

Who can join

Adults 18 to 80, any sex, with Pneumonitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multicenter, exploratory clinical research, to map the radiation or immune checkpoint inhibitor pneumonitis in patients with alveolar lavage single-celled map. Find out the pathogenesis and prevention strategies of radiation or immune checkpoint inhibitor pneumonitis. Specific treatment is given based on the recommendation of the treatment guidelines for radiation or immune checkpoint inhibitor pneumonitis and the results of single cell sequencing, which will become a new technology for clinical application.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Single-cell transcriptome sequencing reveals the immune microenvironment in bronchoalveolar lavage fluid of checkpoint inhibitor-related pneumonitis.
Zheng L, Lin F, Cai D, Zhang L, et al · · 2025 · cited 4× · PMID 40024929 · DOI 10.1007/s00262-025-03983-8
Balancing Innovation and Safety: Prediction, Prevention, and Management of Pneumonitis in Lung Cancer Patients Receiving Novel Anti-Cancer Agents.
Liu S, Wang D, Robinson A, Mates M, et al · · 2025 · PMID 40805219 · DOI 10.3390/cancers17152522

Verify or expand the search:

Other recruiting trials for Pneumonitis

Currently open trials in the same condition.

NCT06860542 — Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis · Phase 2 · recruiting

Other Xinqiao Hospital of Chongqing trials

Trials by the same sponsor.

NCT07347626 — Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis · Phase 3 · not yet recruiting
NCT07349836 — Application of mRNA Immunotherapy Technology in EB Virus Related Diseases · EARLY_PHASE1 · not yet recruiting
NCT07362758 — Exploratory Study on mRNA Therapy Targeting CD19 for the Treatment of Refractory Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
NCT07349849 — Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies · EARLY_PHASE1 · recruiting
NCT06987305 — Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05455034 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xinqiao Hospital of Chongqing
Last refreshed: 14 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05455034.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing